Microbiome Report for Week Ending 3/2/19

Axial Biotherapeutics Raises $25 Million in Series B Financing
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases,